中医定向透药疗法联合阿奇霉素治疗小儿支气管肺炎临床观察

Clinical observation on the treatment of bronchopneumonia in children with Chinese medicine directional penetration therapy combined with azithromycin

目的:探讨中医定向透药疗法联合阿奇霉素治疗小儿支气管肺炎临床疗效及对血清C反应蛋白(CRP)、降钙素原(PCT)和淀粉样蛋白A(SAA)水平影响。方法:选择本院2019年1月—2020年12月支气管肺炎患儿90例,按照随机表法分为研究组和对照组各45例。对照组给予注射用阿奇霉素静脉滴注,10 mg/(kg·d),1次/d,连续4 d,间隔3 d给予阿奇霉素片10 mg/(kg·d)口服,1次/d,连续服用3 d。研究组在对照组基础上联合中医定向透药疗法治疗,30 min/次,2次/d。两组疗程均为10 d。比较两组临床疗效和主要症状体征恢复时间,治疗前后肺功能[1s率(FEV1/FVC)、肺容活量(VC)和呼气高峰流量(PEF)]、血清CRP、PCT和SAA水平变化及不良反应情况。结果:研究组治疗总有效率(95.00%)高于对照组(83.75%)(P<0.05)。研究组发热、气促、咳嗽和湿罗音消失时间短于对照组(P<0.05)。两组治疗后支气管肺炎患儿FEV1/FVC、VC和PEF高于治疗前(P<0.05);研究组治疗后支气管肺炎患儿FEV1/FVC、VC和PEF高于对照组(P<0.05)。两组治疗后支气管肺炎患儿血清CRP、PCT和SAA水平低于治疗前(P<0.05);研究组治疗后支气管肺炎患儿血清CRP、PCT和SAA水平低于对照组(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。结论:中医定向透药疗法联合阿奇霉素治疗小儿支气管肺炎临床疗效显著,可降低CRP、PCT和SAA水平。

Objective:To investigate the clinical efficacy of directional drug penetration therapy of traditional Chinese medicine combined with azithromycin in the treatment of bronchial pneumonia in children and its effect on serum C-reactive protein(CRP),procalcitonin(PCT),and amyloid A(SAA)levels.Methods:A total of 90 children with bronchial pneumonia in our hospital from January 2019 to December 2020 were selected and divided into a study group(n = 45) and a control group(n = 45)according to the random table method.The control group was given azithromycin for injection by intravenous drip,10 mg/(kg·d),once a day for 4 consecutive days.Azithromycin tablets 10 mg/(kg·d) were given orally every 3 days,once a day,for 3 consecutive days.On the basis of the control group,the study group was treated with traditional Chinese medicine directional penetration therapy,30 min/time,twice a day.The course of treatment for the two groups was 10 days.The therapeutic effect and recovery time of main symptoms and signs,lung function [1 s rate(FEV1/FVC),lung volume capacity(VC),and peak expiratory flow(PEF)],serum CRP,PCT and SAA levels,and adverse reactions were compared between the two groups before and after treatment.Results:The total effective rate of the study group(95.00%) was higher than that of the control group(83.75%)(P 0.05).Conclusion:TCM directional drug penetration therapy combined with azithromycin has a significant clinical effect in the treatment of bronchial pneumonia in children,which can reduce the levels of CRP,PCT,and SAA.